Left Anterior Limb of Internal Capsule (ALIC) Infarct — Cognitive & Behavioural Sequelae and Management

Why this infarct causes cognition/behaviour changes

• Frontopontine fibres
• Thalamocortical and corticothalamic fibres (bidirectional frontal lobe ↔ thalamus connections, including DLPFC–thalamic loops)
• Caudate–putaminal fibres

Management Framework

1. Vascular Risk Factor Control (First Priority)

Harrison's 22E states: "At a minimum, treatment should assiduously follow primary stroke prevention guidelines … managing blood pressure, controlling cholesterol, reducing blood sugar, maintaining an active lifestyle, adhering to a heart-healthy diet, losing weight, discontinuing tobacco, and getting healthy sleep." - Harrison's Principles of Internal Medicine 22E

2. Cognitive/Behavioural Rehabilitation

A. Structured Cognitive Training

• Targeted neuropsychological rehabilitation focusing on executive function, attention, and working memory (matching the ALIC frontal-network deficits)
• Computer-assisted cognitive retraining programmes
• Bradley & Daroff's notes VR-based cognitive rehab shows encouraging early results for post-stroke patients - Bradley and Daroff's Neurology in Clinical Practice

B. Repetitive Transcranial Magnetic Stimulation (rTMS)

• rTMS + cognitive training → large effect on global cognition (Hedges' g = 0.780)
• Large effect on executive function (g = 0.769) — exactly the domain disrupted by ALIC infarcts
• Medium improvement in working memory (g = 0.609)
• Medium improvement in ADL (g = 0.418)
• Typical targets: DLPFC; 10 Hz excitatory stimulation on the affected hemisphere
• No benefit on episodic memory or attention alone

C. Physical Exercise

3. Pharmacological Treatment

Maudsley Prescribing Guidelines (15th ed.) states: "Memantine was found to provide significant efficacy in global status. They were all safe and well tolerated … The effect is modest, but in the absence of any other treatments, these agents may be considered in people living with vascular cognitive impairments." - The Maudsley® Prescribing Guidelines in Psychiatry, 15ed

For Behavioural Symptoms (apathy, disinhibition):

• Apathy: Methylphenidate (off-label) has the best evidence for post-stroke apathy; small trials support modest benefit. SSRIs (sertraline, citalopram) for comorbid depression–apathy overlap.
• Agitation/disinhibition: SSRIs first-line; avoid antipsychotics unless necessary (increased stroke risk).

4. Emerging / Adjunctive Therapies

5. Neuropsychiatric Monitoring

• MoCA (Montreal Cognitive Assessment) — sensitive to executive/attention deficits
• FAB (Frontal Assessment Battery) — directly targets this lesion's network
• Trail Making Test B, CLOX, FAS verbal fluency — executive battery
• Depression screening (PHQ-9) — depression accelerates cognitive decline post-stroke

Summary of Priorities

1. Aggressive vascular risk factor control (BP <130/80, statin, antiplatelet)
2. Multidisciplinary cognitive rehabilitation (neuropsychologist + OT)
3. rTMS + cognitive training (strongest evidence for executive function)
4. Consider donepezil 10 mg or memantine (modest but reasonable in absence of alternatives)
5. Treat comorbid depression/apathy (SSRI ± methylphenidate for apathy)
6. Serial MoCA + FAB to monitor trajectory
7. Physical exercise programme

Blood Pressure Control Timing After Ischemic Stroke — Complete Framework

The Core Principle: Early Aggressive Lowering is Harmful

Phase 1: Acute Phase (First 24 Hours)

If the patient did NOT receive thrombolysis (tPA) or thrombectomy:

Washington Manual: "BP should not be lowered acutely unless necessary for acute coronary syndrome, CHF, hypertensive crisis with end-organ involvement, or SBP >220 or DBP >120 mmHg. BP lowering should proceed cautiously, with 15% during the first 24 hours being a reasonable goal." - The Washington Manual of Medical Therapeutics

If patient received IV tPA (thrombolysis):

AHA/ASA and ESO guidelines per Comprehensive Clinical Nephrology, 7th Edition: pre-thrombolysis target <185/110, post-thrombolysis maintenance <180/105 for 24 hours.

If patient received mechanical thrombectomy:

Phase 2: 24–72 Hours (Stabilisation Phase)

• Resume or initiate antihypertensives only when neurological status has stabilised
• Avoid if patient is still deteriorating or fluctuating
• If pre-stroke antihypertensives were being taken, restart at reduced dose (to avoid precipitous drop, especially in non-compliant patients)

Adams and Victor's: "The treatment of previously unappreciated hypertension is preferably deferred until the neurologic deficit has stabilised. It may be prudent to avoid antihypertensive drugs in the first few days unless there is active myocardial ischaemia or the BP is high enough to pose a risk to other organs." - Adams and Victor's Principles of Neurology, 12th Edition

Phase 3: After 72 Hours / Sub-acute Phase

• Initiate or optimise long-term antihypertensive therapy
• This is when BP control demonstrably reduces recurrent stroke risk and cognitive decline
• Gradual titration is preferred — avoid sudden drops

Phase 4: Long-term (Secondary Prevention)

• ACE inhibitors or ARBs (e.g., perindopril, ramipril, telmisartan) — PROGRESS trial
• Thiazide diuretics (e.g., indapamide) — often combined with ACEi
• Avoid beta-blockers as first-line unless cardiac indication (less effective for stroke prevention)

Summary Table

Specific Evaluation Required for Left ALIC Infarct (Beyond Carotid Doppler & 2D Echo)

1. Neuroimaging

Harrison's 22E: "Because MRA images the entire arterial system relevant to stroke, with the exception of the heart, much of the clinician's stroke workup can be completed with this single imaging study." - Harrison's Principles of Internal Medicine 22E

2. Cardiac Monitoring (Arrhythmia Detection)

"The use of extended cardiac rhythm monitoring (30-day event-triggered loop monitoring or an implanted monitor) reveals occult atrial fibrillation in up to 25% of patients with an otherwise cryptogenic stroke." - Goldman-Cecil Medicine

3. Cardiac Structural Evaluation (Beyond TTE/2D Echo)

4. Haematological & Laboratory Workup

5. Thrombophilia Screen (Selective — especially if young, no obvious risk factors, or recurrent strokes)

• Antiphospholipid antibodies: Anticardiolipin IgG/IgM, β2-glycoprotein-1 IgG/IgM, Lupus anticoagulant
• Protein C activity
• Protein S (total and free antigen)
• Antithrombin III activity
• Factor V Leiden mutation
• Prothrombin G20210A mutation
• Plasma homocysteine
• Fibrinogen
• Haemoglobin electrophoresis (if sickle cell suspected)

Note: Thrombophilia testing should be done off anticoagulation and ideally in a non-acute setting (acute-phase proteins alter results).

6. Vasculitis / Autoimmune Screen (if clinically suggested)

• ANA, ANCA, anti-dsDNA
• Complement C3/C4
• CSF examination — if CNS vasculitis or infectious aetiology suspected

7. Specialised Investigations (if still cryptogenic after standard workup)

Diagnostic evaluation of cryptogenic ischemic stroke — Goldman-Cecil Medicine

• Genetic testing: CADASIL (NOTCH3), Fabry disease (α-galactosidase A), MELAS (mitochondrial) — consider in young patients with white matter disease or family history
• Prolonged outpatient loop recording (1–3 years) for paroxysmal AF detection
• Aortic arch imaging (TEE or CTA) — significant source of artery-to-artery emboli
• Brain biopsy — only if CNS vasculitis or unusual pathology suspected

For Your Specific Patient (Left ALIC Infarct, 2.5×1.5 cm)